MDS UK tribute to Professor Rodney Taylor (1942-2017)

It is with immense sadness that we announce the death of our past Chairman, Professor Rodney Taylor on 3rd May 2017, after his MDS progressed to AML.

Euroblood Net

MDS UK Patient Support Group Chairman

Rodney was diagnosed with MDS in 2006 and was invited to become Deputy Chairman when our little patient group was still in its infancy.

Following the death of the then Chairman David Hall, Rodney became Chairman in 2010 and thereafter dedicated an immense amount of his spare time working for and leading the group until late 2016, when it was clear his MDS had progressed and no further treatment was possible.

Euroblood Net

Rodney's achievements for all MDS patients: NICE approval of Azacitidine

Rodney was an amazing, witty, gentle, very funny and extremely talented Chairman. MDS UK achieved an incredible amount of work under his guidance. The most significant achievement being the NICE approval of the drug Azacitidine in 2010. The MDS community as a whole owes him a huge debt of gratitude for this work which spanned 2 years.

You can read more about Rodney and his amazing career here:

During his time as Chairman, Rodney met with all stakeholders in the medical and pharmaceutical MDS sector and was immensely appreciated, liked and respected for his views, understanding, advice and personality across all professional and patient groups alike.

Euroblood Net
Professor Rodney Taylor with an MDS Campaigner

Passionate about a good doctor-patient communication

Rodney had two topics he was particularly passionate about resulting from his being a medical doctor as well as a patient.

The first topic was the Doctor/Patient actual communication – as to him this was absolute key to a good consultation, relationship and care overall.
Rodney taught about this and one of his wishes was to re-instate regular courses for physicians about Advanced Communication Skills.
He knew this was a skill that can be improved – and could immensely assist clinicians and therefore also patients – especially in today’s stretched NHS.

Rodney's passion for Quality of Life for MDS patients

The second topic was equally close to his heart – Quality of Life (QOL) for patients. The fact that survival is not always the ultimate aim and that patients’ wishes, desires and situations can differ greatly and need to be respected at all times. Rodney believed that QOL must be measured and assessed on a regular basis at every point in a patient’s life – from diagnosis to death – and acted upon. Rodney believed totally in the QOL of MDS patients and followed his belief in his own treatment.

Rodney was treated with Azacitidine for almost 5 years before undergoing a stem cell transplant at age 71. Three years after the transplant his QOL of life had deteriorated and he did not wish to undergo any further experimental treatments that would have meant more intensive hospital care.

Despite a few serious side-effects over the course of those three years, Rodney carried on working with the CEO and the new Chair until the last few weeks of his life. He continued to give valuable advice, opinions and views on the way ahead for MDS UK, which was much appreciated and extremely helpful to the incoming Chair. His thoughts and views were always given in his caring, considerate style – and his lovely sense of humour.

Euroblood Net
Euroblood Net
Euroblood Net

In Rodney Taylor's Memory

We at MDS UK have grown, learnt and improved thanks to Rodney’s leadership. His death is an immense loss to us. We will maintain our work and dedication to patient support and services – emphasising QOL and good communication at every opportunity - in his memory.

MDS UK was extremely important to him and the work we did was very close to his heart – and so were all the committee members and patients. He cared very deeply – and never missed an opportunity to express it. Equally – Rodney was very close to our heart too.

Rodney had not made his wishes known to MDS UK whilst alive, but he had arranged to have memorial donations directed to our organisation as an option.

We have therefore set up a page in his memory – where you can also leave a message which will be read by all family and friends:

His death comes shortly after that of a previous MDS UK Committee Member, Sharon Berger, who passed away due to similar reasons, after a second transplant.

With the increased research being conducted into MDS we all hope, as Rodney did, that a real cure or at least improved treatments, are on the way for patients.

We thank all the friends, colleagues and patients who have sent in tributes and caring thoughts regarding Rodney. We are very grateful and will pass them on to his family.

We offer our most sincere and caring condolences to his wife Janet, to his children Alice, Beatrice and Romilly and to his many grand-children.

Rodney was a man of deep faith and quiet conviction. There is a Native American saying which says "when you were born you cried and the world rejoiced. Live your life so that when you die the world cries and you rejoice”. Rodney certainly lived his life well and I am sure has received a very warm welcome in heaven. May he rest in peace.

If you wish to leave a few words about Rodney, or a comment, tribute, thought – please email us on – with the Subject: In memory of Rodney.

We will then publish your comments on this page – with your name (if you wish), or anonymously if you prefer.

Very many thanks in advance.

What is CAR T cell therapy? Learn about how this immunotherapy works

CAR T cell therapy aims to boost the immune system to attack tumor cells

Cell therapies, sometimes called “living therapies,” are an especially promising and rapidly growing area of cancer research. One approach that’s been pioneered by Memorial Sloan Kettering researchers, led by investigator Michel Sadelain, is called CAR T cell immunotherapy. This type of targeted immunotherapy aims to boost the immune system by giving immune cells the information they need to better recognize tumor cells as foreign and attack them.

How does it work?

The technique involves filtering white blood cells called T cells from a patient’s blood and introducing a new gene into those cells. A disabled virus called a vector is used to carry the gene inside the T cells and insert it into the cells’ genomes.

The gene programs the T cells to make a chimeric antigen receptor (CAR), which enables them to recognize a specific protein that’s present in cancer cells. The CAR T cells are then grown in the laboratory and infused back into the patient, where they seek out and destroy the cancer.

CAR T cell therapy is currently being evaluated in the clinic at MSK for certain types of leukemia and lymphoma. In this approach, T cells are genetically engineered to recognize a protein called CD19, which is found on the surface of blood cells called B cells. In the largest study reported so far, for adult patients with B cell acute lymphoblastic leukemia — a rapidly progressing form of blood cancer — a report published by MSK researchers last year found that 88 percent of patients responded to the therapy. In late 2014, the US Food and Drug Administration granted MSK Breakthrough Therapy Designation for its CD19 CAR therapy.

The science behind it

  • A chimeric antigen receptor (CAR) helps T cells identify tumors.
  • These T cells then recognize tumors as foreign and attack them.
  • CAR T cell therapy is being used to treat leukemia and other cancers.

Take a look at current MDS clinical trials

MDS Treatment: What to Expect from a Visit to a Consultant

Dr. Christopher Dalley & Dr. Timothy Chevassut – Haematologists at Brighton and Sussex University Hospitals Trust and Royal Sussex Hospital NHS Trust - give an account of how they discuss diagnosis and treatment with their MDS patients. Watch the video and read the transcript below.

What are the typical issues when you first diagnose a patient with MDS and when may you tell patients about the existence of a support group?

I think it's really difficult sometimes for patients to understand what goes on in the blood. So, for me, it's really important to try to give an appropriate explanation about what myelodysplasia is and the symptoms they may have. Of course, because it is a significant blood disorder with lots of anxiety, you want to be able to support the patient when you give the diagnosis and try to allay any anxieties that they may have.

In terms of the diagnosis and explaining the diagnosis, there's lots of written information available, so it's very important for patients to access that (and I often give that to patients at first diagnosis or subsequent visits) and also to be able to access support from the MDS Patients Forum. So normally I give that information at the time of diagnosis, and a clinical nurse specialist who I work closely with will also reiterate that to patients.

And how have you seen the Patient Support Group activities and materials help specific patients?

Well, a lot of patients have questions and I think, in this day and age, most patients want to have information that they can access and it's not always the case that you can access that information in the clinic or have all the questions answered in the clinic, to be honest. So I find that if they have additional support they can access that information, talk to other patients and experts and to other family members from across the UK. I think that's really important and a great help for patients and families.

Tim, how frequently do you discuss clinical trials with your MDS patients and have you heard of any trials today that sound interesting or promising?

We discuss clinical trials as and when it's appropriate to do so. Obviously, we have established treatments by way of Azacitidine for patients newly diagnosed with high-risk myelodysplasia but, of course, not all patients respond to those treatments. Some will progress to leukaemia, others won't have an adequate response in terms of their blood count. So there are many occasions when we have to look at alternative treatments for these patients and that really would be the occasion for bringing up clinical trial opportunities both within Brighton and elsewhere, for instance at Kings or elsewhere in London.

And what kind of difficulties do you encounter with explaining the concept of trials to patients? Have you got an example of a really successful trial for a patient?

I think the concept of clinical trials and the problems perhaps we encounter when we discuss these with patients are conveying the sort of complexity of the study in simple terms that they're able to get their head round. These are often very complicated trials with a lot of patient information with them. But, in essence, the question that all clinical trials are trying to answer is whether new treatments that are becoming available for us are better than standard treatment. For most of the patients who fail Azacitidine, there really isn't any "Plan B", so we are very keen to try and understand where these newer therapies will fit in future treatment for our patients.

You asked about clinical trials that we have ongoing in Brighton at the moment: we're looking at antibody-based therapies, at targeted therapies; we're looking at Immune Checkpoint Inhibitor therapy which is very promising in the solid tumour field, but not yet established in blood cancers; we're looking at antisense therapy, hopefully next year, in patients who have refractory anaemia or anaemia that's no longer responding to Erythropoietin, for instance.

So we have some interesting trials locally and obviously many others elsewhere in the country. The important thing is giving patients the opportunity to take part in these studies and make these studies available to them.

Second Opinions are Welcomed says Dr. Simone Green

How is a patient's treatment discussed and managed?

Sophie Wintrich, Chief Executive of the MDS UK Patient Support Group, interviewed Dr. Simone Green – Haematologist at Hull and East Yorkshire Hospitals, NHS Trust. Watch the video and read the transcript below.

What are the benefits of patients’ groups? What difference does it make to you personally, in your daily consultations, to have a well-informed or empowered patient?

I think these patients tend to be more involved in their ongoing care. They come to the consultation with information and it makes the consultation flow much easier. They know what they want out of their management, they know what they want for their long-term care. It just makes the consultation easier when you need to discuss the diagnosis, the prognosis, etc.

Are there any drawbacks to having a patient who is “over-informed”?

It always good for patients to be informed. But we sometimes encounter difficulties when a patient becomes disappointed when a new drug, for example, is not available to them in their centre. With MDS there are new drugs coming out, most of them available in clinical trial studies only. So, if a study is not available at their centre or somewhere that is easily accessible, it’s disappointing for the patient. That’s one difficulty.

One topic that comes up very often in our patients’ calls is second, or what we call 'additional', opinions. What are your views on patients who request an additional opinion? Does it offend you if a patient asks for an additional opinion when he is seen by you?

One of the reasons that I went into haematology is that we work as a team - there is no individualised treatment, the treatment is all evidence based and we work as a team managing our patients. I welcome a second opinion, it’s always good to have fresh eyes, bringing a new perspective on how to manage a patient. It involves someone else’s expertise.

What is the difference for patients between being discussed in an MDT1 and going for an additional opinion somewhere else, as you have just explained?

An MDT involves decision making within a local team, or a local network in some situations. So obviously that will take into account the local guidelines, which are evidence based, but it will be tailored to that local environment. It looks at the local resources available and the local expertise as well - so the clinical experience within that centre. A second opinion will be outside of that local setting, taking into account someone else’s experience and expertise, and probably it would have a perspective based on a lot more information and more resources.

1 A Multidisciplinary Team (MDT) is a group of health care workers and social care professionals who are experts in different areas with different professional backgrounds, united as a team for planning and implementing treatment programs for complex medical conditions.

"Well-informed patients tend to be more involved in their daily care. They come to the consultation with information and it makes the consultation flow much easier. They know what they want out of their management, they know what they want for their long-term care..." Dr. Simone Green

Sharon Berger, one of the founders of MDS Patient Group, a campaigner and a friend

We are deeply saddened by the news that Sharon Berger passed away a few days ago. Sharon was one of the founders of the very original MDS patient group back in 2007, when that group was still in its infancy - together with Fiona Pirilla and Kes Grant.

Euroblood Net

MDS UK Patient Support Group Treasurer

In 2008 and thereafter, when the group grew, thanks to the help and advice of the MDS Foundation, the financial support of Novartis and Celgene (and their very dedicated patient relation staff members) and the great leadership of chairman and MDS patient David Hall, Sharon became the treasurer of MDS UK, later together with her husband Stephen, until they resigned a few years later, due to Sharon's MDS progressing to AML.

MDS UK is very grateful to the time and work both Sharon and Stephen contributed over the years to the organisation.
All members who got to know them over the years, working and growing together as a group are deeply saddened and convey their condolences to the family.

Recruiting stem cell donors of Jewish origin: the great legacy of Sharon

The MDS and AML community owe a huge debt of gratitude to the Berger family who took on the extraordinary task of recruiting stem cell donors of Jewish origin, when Sharon's needed her first transplant.

Sharon had a very rare and mixed ethnic background of Russian and Ashkenazi Jewish origin, which meant a very long and difficult search for a suitable donor.

Her children Jonni and Caroline created an incredible campaign to mobilise the Jewish community to register as donors.

It grew the percentage of Jewish stem cell donors by over a 1000% and did finally result in finding a donor.

The work of Caroline and Jonni are an inspiration to all patients, organisations and haematologists, as to what can be achieved when everyone works together.

Their efforts had a huge impact everywhere and are a tribute to their Mum, who went through so much, but always brave, strong and positive.
We convey our sincere condolences to Jonni, Caroline, Stephen, Sharon's sister and all the family and many friends.

Watch the videos from the UK MDS Forum Education Day 2016

The following videos come from the annual UK MDS Forum Education Day 2016, which took place in London on 11th November 2016.

The day is targeted at all haematologists in the UK and Ireland who deal with MDS patients. Its aim is to provide information and updates on the most advanced scientific and clinical research in MDS. Please have a look at the agenda here.

We are now able to make the videos available online. Although these were initially intended for health professionals, patients and their families are also invited to watch. Our aim is to make this valuable information more widely available, not only to clinicians and nurses but also to patients, in order to educate and empower them, as well as explaining the fantastic research that goes on in MDS.

Immunophenotyping in MDS - Prof. Arjan Van de Loosdrecht

Case history: Immunophenotyping an MDS patient - Dr. Robin Ireland

King's Myeloid Gene Panel Development - Dr. Steve Best

CHIP / ICUS / CCUS What Does It Mean in the Clinical Practice? - Dr. Catherine Cargo

MDS Initiating Cells and Clonal Evolution - Prof. Dominique-Bonnet

Integrated Functional and Genomic Analysis of Leukaemia Stem Cells in AML - Dr. Lynn Quek

Please feel free to use and share these clips, but please credit MDS UK Patient Support Group, as well as UK MDS Forum.

“One of the biggest challenges for a patient is they’ve never heard of MDS” says Prof David Bowen

Sophie Wintrich, Chief Executive of the MDS UK Patient Support Group, interviewed Prof. David Bowen – Consultant Haematologist at St James University Hospital, Leeds. Watch the video and read the excerpts below.

What are the typical issues when you first diagnose a patient with MDS?

What difference does it make to you personally - in your daily consultations – to have a well-informed or empowered patient? Benefits/drawbacks?

"If the patient has some idea about what MDS is and they come with a set of questions from their own readings, that is a useful framework to find the details that are specific to them.
I usually use the MDS Patients Support Booklet... I mark the booklet and the sections that are relevant to them..." Prof. David Bowen

How important is it to have a treatment plan for MDS? Why?

What kind of difficulties do you encounter with explaining the concept of trials to patients? Do you have examples of a successful trial for a patient?

Clinical trials and the European MDS Registry Trial

Question: How frequently do you discuss clinical trials with your MDS patients? Are there any current trials that you are discussing at the moment?

Prof. Bowen: We are a major centre for MDS research, so we are very focused on clinical trials here in Leeds. Most of our patients are suitable for at least the Registry Trial. The Registry is essentially an opportunity to collect information about every patient's type of MDS and to use that information going forward, document that information about how that patient's MDS develops and what sort of treatment they have and what their response is to treatment.
That is a trial, a Registry Trial, very important to generate data that we call "real world data" or "community data" to record information about patients who are not in clinical trials for new drugs, but are nevertheless managed using conventional treatments.

How frequently do you discuss clinical trials with your MDS patients? Any trials discussed today that sound interesting or promising?

How do you address and explore quality of life issues with patients and their families?

What are your views on patients who request an additional opinion? How do you generally react? Does it offend you?

What is the difference for patients between being discussed in an MDT – and going for a 2nd or additional opinion somewhere else?

Where are we at in terms of more personalised treatment for MDS?

Should we start to insist that all MDS patients must have a genetic mutation test to establish what treatments may work out best for them?

What would be the research benefit of collecting tissue samples from all MDS patients? How can patients ensure this happens?

A New European Network, EuroBloodNet, will ensure better care for MDS patients

Patients with rare blood disorders will benefit from networks of excellence across Europe

EuroBloodNet was launched at the third conference on European Reference Networks (ERNs) yesterday in Vilnius, Lithuania

Euroblood Net

European Reference Networks (ERN) is an initiative of the European Commission and consists of networks of healthcare providers and centres of excellence across Europe aimed at improving quality, safety, and access to highly specialised healthcare.

Through these networks, healthcare providers have access to a much larger knowledge pool and patients have better chances of receiving the best treatment.

EuroBloodNet, the European Reference Network for rare hematological diseases, brings together 66 highly specialized hospital centres with expertise on malignant and non-malignant rare blood diseases.

MDS Patients are represented

Patient involvement is key, so the haematology patient community elected five representatives for EuroBloodNet. Sophie Wintrich, from the MDS UK Patient Support Group, is among them, to ensure that the patient voice is fully represented.

This is a great achievement and a proof that the role of patients is increasingly recognised in clinical care.

After their first meeting in January 2017 in Paris, EuroBloodNet will gather again at the Congress of the European Hematology Association, between 22-25 June, in Madrid, Spain.

Personalised Treatment for MDS Patients: Not Far-Off says Dr Catherine Cargo

Where are we exactly with respect to personalised treatment for MDS patients?

Sophie Wintrich, Chief Executive of MDS Patients Support Group interviewed Dr Catherine Cargo – Consultant Haematologist at St James University Hospital – Leeds. Watch the video and read the transcript below.

MDS: A disease where everybody is different

When we think about personalised treatment we think about a disease where everybody is different. We group all these patients together, but everybody’s disease has slightly different changes in the genetic make-up of the disease and also how they progress or how they do in the duration of their disease.

The really interesting thing about where we are with MDS now is that we will hopefully be able to personalise treatment for the patient so we can look at the patient - look at their individual disease and what abnormalities they have - and then potentially target those abnormalities with specific drugs.

"We are starting to see particular drugs which target specific abnormalities"

I think that it is an exciting time, because we are now starting to see particular drugs which target abnormalities or genetic mutations which are found in MDS and certain patients will respond very well to those.

Another interesting thing is that we can use technologies to identify patients who will respond to more generic drugs - drugs that we at the minute give to everybody. There will be certain patients who will respond very well to those and we should be able to use a lot of these new technologies to identify patients who will respond better, and give patients an idea of how they are going to do on treatment and what their future holds.

Does it mean that all patients must have genetic mutation test?

Q: Does that mean we should start to insist that all patients must have genetic mutation tests to establish which treatments may work out best for them?

I think we are getting to the point where this information is going to be useful in the clinic. We are still gathering information and the tests that we use are still quite difficult and quite complicated for a lot of different labs. And at the minute we don’t have a very standardized way of doing this, so there is quite a lot of work that needs to be done before we get to the point where we can offer this as a blanket test for everybody. I think we will get there and it is something that we will do in the future. It is an option, we can do it in the UK. It’s exciting and I think it will be offered in future, but we shouldn't necessarily be insisting on it now. There are certain cases where it will be particularly helpful and it’s definitely being applied in the clinical trial setting. It will be very interesting gathering that information. At some point in the future we will be able to insist that patients do get this testing done.

Q: How far off is this future?
I don’t think that it is that far off. This is something that we are going to be doing quite soon. The technology is there. It’s becoming cheaper and cheaper to do, and it’s becoming easier to do, even within the NHS. So I think within the next couple of years we will be seeing this as a routine test for MDS patients.

2nd Stem Cell Transplants Funding Re-instated Thanks to Your Support!

NHS England will fund 2nd stem cell transplants for patients whose blood cancer relapses

Since NHS England initially announced in December 2016 that it wouldn’t fund second transplants, more than 25,000 people joined our campaign to reverse the decision.

Thanks to every single person that signed the petitions, and wrote to their MPs. We all did it together.

Thanks to colleagues at Anthony Nolan, all other blood cancer charities, Emma Paine, Mark Tami MP, the APPG on Stem Cell Transplant, many MPs and clinicians, Sasha Jones and friends.

An extra-special thanks to the Hepburn family, who showed so much courage and campaigned selflessly after Gavin's death. We owe them a huge debt of gratitude.

Second Stem Cells Transplant Campaign

NHS Announcement in detail: routine funding for 2nd stem cell transplants for patients who relapse more than a year after their 1st transplant

On Friday 24 February NHS England announced that they will routinely fund second stem cell transplants for patients who relapse more than one year after their first transplant. This replaces the announcement in December 2016 that second stem cell transplants were ‘not currently affordable’.

Every year, a small number of patients with a blood cancer or blood disorder who have already received one stem cell transplant from a donor will unfortunately relapse (their disease will come back). For some of these patients, their doctor might recommend a second donor stem cell transplant. It is estimated that 16 to 20 people every year in England will need a second transplant because their blood cancer or blood disorder has relapsed.

This decision affects a small number of patients in England who:
• have received a first donor (allogenic) stem cell transplant;
• were in complete remission;
• subsequently relapsed more than 12 months after their first transplant; and
• their doctor now recommends a second stem cell transplant.

This decision does not affect patients who suffer graft failure (their first transplant fails) or patients who have received a first transplant using their own cells (autologous). This decision only affects patients in England; patients in other parts of the UK are not affected.

Why does this decision only apply to patients who relapsed more than 12 months after their first transplant?

The recommendation of clinical experts is that patients who relapse more than 12 months after their first transplant have the best chance of a successful second transplant. Unfortunately, there is weak evidence for the effectiveness of second transplants for patients who relapse within a year of their first donor transplant.

Read More: Blood and Marrow Transplantation

Join the Register!

Free donations by shopping